XTL Biopharmaceuticals Ltd. Sponsored ADR (XTLB)
NASDAQ:XTLB
Holding XTLB?
Track your performance easily

XTL Biopharmaceuticals Ltd. Sponsored ADR (XTLB) Income Statement

95 Followers

XTL Biopharmaceuticals Ltd. Sponsored ADR Income Statement

Last quarter (Q ), XTL Biopharmaceuticals Ltd. Sponsored ADR's total revenue was $―, a decrease of ― from the same quarter last year. In Q, XTL Biopharmaceuticals Ltd. Sponsored ADR's net income was $―. See XTL Biopharmaceuticals Ltd. Sponsored ADR’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
------
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 406.00K$ 765.00K$ 880.00K$ 1.03M$ -948.00K$ -842.00K
Operating Income
$ -406.00K$ -765.00K$ -880.00K$ -1.03M$ -948.00K$ -842.00K
Net Non Operating Interest Income Expense
$ 4.00K$ -36.00K$ -468.00K$ 1.47M$ -2.01M$ -505.00K
Other Income Expense
$ -704.00K$ 981.00K----
Pretax Income
$ -1.11M$ -1.78M$ -1.35M$ 435.00K$ -2.95M$ -1.35M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -1.11M$ -1.78M$ -1.35M$ 435.00K$ -2.95M$ -1.35M
Basic EPS
$ -0.24---$ -0.01-
Diluted EPS
$ -0.24---$ -0.01-
Basic Average Shares
$ 10.90M$ 544.91M$ 544.91M$ 532.00M$ 514.21M$ 514.21M
Diluted Average Shares
$ 10.90M$ 544.91M$ 544.91M$ 532.00M--
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 406.00K$ 765.00K$ 880.00K$ 1.03M$ -948.00K$ -842.00K
Net Income From Continuing And Discontinued Operation
$ -1.11M$ -1.78M$ -1.35M$ 435.00K$ -2.95M$ -1.35M
Normalized Income
$ -402.00K$ -1.31M----
Interest Expense
$ 11.00K-----
EBIT
$ -1.17M$ -1.75M$ -1.35M$ -1.03M$ -948.00K$ -842.00K
EBITDA
$ -1.17M$ -1.75M$ -1.35M$ -1.03M--
Currency in USD

XTL Biopharmaceuticals Ltd. Sponsored ADR Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis